Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
1.730
-0.230 (-11.73%)
Oct 3, 2025, 4:00 PM EDT - Market closed

Liminatus Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-3.55-3.55-4.98-2.93-5.61
Depreciation & Amortization
----0
Asset Writedown & Restructuring Costs
---0.90.9
Other Operating Activities
----1.5
Change in Accounts Payable
-0.01-0.010.430.090.04
Change in Other Net Operating Assets
2.112.111.211.073.01
Operating Cash Flow
-1.45-1.45-3.35-0.87-0.17
Investing Cash Flow
-2.85-2.85-0.82--
Short-Term Debt Issued
-3.923.419.44-
Total Debt Issued
3.923.923.419.44-
Short-Term Debt Repaid
---3.86-7.03-
Total Debt Repaid
---3.86-7.03-
Net Debt Issued (Repaid)
3.923.92-0.452.42-
Issuance of Common Stock
---4.2-
Repurchase of Common Stock
----0.7-
Financing Cash Flow
3.923.92-0.455.92-
Net Cash Flow
-0.38-0.38-4.615.05-0.17
Cash Interest Paid
---0.5-
Levered Free Cash Flow
--2.92-2.3-0.67-
Unlevered Free Cash Flow
--2.71-2.19-0.53-
Change in Working Capital
2.12.11.641.163.05
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q